Interstitial Cystitis Clinical Trial
— IC/BPSOfficial title:
Supervised Exercise as a Therapeutic Strategy for Interstitial Cystitis/Bladder Pain Syndrome
In this study, the efficacy of exercise to improve interstitial cystitis/bladder pain syndrome symptoms and quality of life will be investigated.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Adult females (>18 years and <80 years) with a previously established clinical diagnosis of Interstitial cystitis/bladder pain syndrome (IC/BPS) will be eligible to participate - Must speak English - The clinical diagnosis of IC/BPS will be based on the recently published American Urological Association Guidelines definition: "An unpleasant sensation (pain, pressure, or discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms for more than six weeks duration, in the absence of infection or other identifiable causes" - The diagnosis will be confirmed by a urologist who specializes in the treatment of patients with IC/BPS Exclusion Criteria: - Study participants must be fully ambulatory without the use of a cane, walker, or wheelchair - Study participants must be able to tolerate moderate aerobic exercise. It will also be required that a physician clear any subjects entering the exercise program who have signs and symptoms suggestive of cardiovascular, cerebrovascular, metabolic, or renal disease and have been active 3 days per week for 30 minutes each day - Any history of bladder cancer, uterine cancer, ovarian cancer, vaginal cancer, the current placement of a catheter, urethral diverticulum, spinal cord injury, stroke, Parkinson's disease, multiple sclerosis, spina bifida, cyclophosphamide treatment, radiation cystitis, bladder tuberculosis, or are experiencing an active genital herpes episode - Pregnant women are not eligible for this study |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences | University of North Carolina, Greensboro |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in inflammatory urinary biomarkers | Urine samples will be obtained at baseline and at the end of the 4 month exercise period from participants. The urine will then be analyzed for biomarkers of inflammation using a Luminex High Performance Assay. Any decrease in the levels of biomarkers of inflammation in the urine is the outcome of interest. | baseline, 6 weeks | |
Other | Post-regimen review | After the exercise program concludes, participants will be contacted via phone or email and asked to comment on the program and make suggestions for improvement. This will include things such as if they would recommend the program to friends/family, if they have continued to exercise and/or will continue to exercise on their own time, and any portions of the program they would change or do differently. | after week 6 | |
Primary | Interstitial Cystitis Symptom Index (ICSI) Scores | Participants answer a series of questions to get a final score. Scores range from 0-20, with 0 being no symptoms and 20 the most severe. | baseline | |
Primary | Interstitial Cystitis Problem (ICPI) Index Scores | Participants answer a series of questions to get a final score. Scores range from 0-16, with 0 being no symptoms and 16 the most severe. | week 3 | |
Primary | Interstitial Cystitis Symptom Index (ICSI) Scores | Participants answer a series of questions to get a final score. Scores range from 0-20, with 0 being no symptoms and 20 the most severe. | week 3 | |
Primary | Interstitial Cystitis Problem (ICPI) Index Scores | Participants answer a series of questions to get a final score. Scores range from 0-16, with 0 being no symptoms and 16 the most severe. | week 6 | |
Primary | Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) Scores | This survey is used to grade people with chronic pelvic pain. Participants answer a series of questions. Scores range between 0 and 35, and studies have indicated that a score greater than 12 is indicative of significant symptoms | baseline | |
Primary | Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) Scores | This survey is used to grade people with chronic pelvic pain. Participants answer a series of questions. Scores range between 0 and 35, and studies have indicated that a score greater than 12 is indicative of significant symptoms | week 3 | |
Primary | Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) Scores | This survey is used to grade people with chronic pelvic pain. Participants answer a series of questions. Scores range between 0 and 35, and studies have indicated that a score greater than 12 is indicative of significant symptoms | week 6 | |
Secondary | Change in the Short Form 36 (SF-36) Health Survey Scores | The SF-36 is a questionnaire that consists of 8 subsections of 36 total questions. The sections are Physical functioning (10 items), Role limitations due to physical health (4 items), Role limitations due to emotional problems (4 items), Energy/fatigue (4 items), Emotional well-being (5 items), Social functioning (2 items), Pain (2 items), General health (5 items). Aggregate scores for each domain range from 0 to 100, compiled as a percentage - where the higher the score, the more favorable the health state of the patient. | baseline, week 3, week 6 | |
Secondary | Changes in Composite Autonomic Symptom Score (COMPASS-31) Scores | The test has 6 domains looking at autonomic symptoms: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor. The six domain scores sum to a total COMPASS 31 score of 0 to 100, and a higher COMPASS 31 score indicates more severe autonomic symptoms. | baseline, week 3, week 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Completed |
NCT03282318 -
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT03463499 -
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
|
N/A | |
Completed |
NCT02898220 -
Trans-MAPP II Study of Urologic Chronic Pelvin Pain
|
||
Terminated |
NCT02591199 -
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT02247557 -
Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis
|
Phase 2 | |
Active, not recruiting |
NCT01731470 -
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00971568 -
Urinary Biomarkers Characteristic to Interstitial Cystitis
|
N/A | |
Completed |
NCT00527917 -
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Recruiting |
NCT00094874 -
Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms
|
Phase 3 | |
Terminated |
NCT00086684 -
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
|
Phase 4 | |
Recruiting |
NCT04845217 -
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT04401176 -
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT05147779 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
|
Phase 1 | |
Suspended |
NCT04450316 -
Low-dose Naltrexone for Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04010513 -
Hypnosis for Bladder Pain Syndrome
|
N/A | |
Completed |
NCT05179460 -
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
|
||
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A |